Kevin Robinson | Editor

Articles and archive:

Active Nutrition | Analysis | Cell & Gene Therapy | Containment | Contamination Control | Digital | Distribution | Dosage Forms | Drug Delivery | Finance | Food | Hi Tech Manufacturing | Ingredients | Logistics | Manufacturing | Marketing | Media | Medical Devices | Packaging | Pharma 5.0 | Pharmaceutical | Regulatory | Research & Development | Sustainability

Dr Kevin Robinson is a former molecular biologist turned writer, publishing executive and editor with extensive media experience in the life science, pharmaceutical and nutraceutical sectors

Kevin Robinson

Related content

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Back to basics: a simple guide to checkweighing in pharmaceutical production

Back to basics: a simple guide to checkweighing in pharmaceutical production

Mettler-Toledo’s Miriam Krechlok tells Dr Kevin Robinson how checkweighing helps pharmaceutical manufacturers to verify product completeness, control fill levels and maintain compliance, safety and efficiency
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development
Where nanoengineering meets drug formulation

Where nanoengineering meets drug formulation

How Nanexa is turning short-acting drugs into long-acting injectables
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
The DNA bottleneck: how synthetic manufacturing could unlock the next wave of gene editing therapies

The DNA bottleneck: how synthetic manufacturing could unlock the next wave of gene editing therapies

As gene-editing therapies evolve towards increasingly complex applications, 4basebio CEO Amy Walker (AW) tells Dr Kevin Robinson (KSR) how advances in scalable enzymatic DNA manufacturing could help overcome critical supply bottlenecks and accelerate the development of next-generation genetic medicines
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery
Wearable pumps and subcutaneous delivery: a new frontier in heart failure management

Wearable pumps and subcutaneous delivery: a new frontier in heart failure management

Two recent developments are reshaping how drug delivery technology can move treatment out of the clinic and into patients’ everyday lives — with implications for both formulation science and device manufacturing
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery
Addressing Project Optimus with the Net Treatment Benefit framework

Addressing Project Optimus with the Net Treatment Benefit framework

Aligned with the US FDA's Project Optimus initiative, the Net Treatment Benefit framework offers an integrated approach to dose optimisation that balances efficacy, safety and tolerability across multiple prioritised outcomes. Dr Kevin Robinson (KSR) spoke to Pascal Piedbois (PP) to find out more
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery
Inhaled therapies advance as clinical trial data signal progress on two respiratory fronts

Inhaled therapies advance as clinical trial data signal progress on two respiratory fronts

Two separate clinical programmes have reported encouraging progress in the development of inhaled therapies for respiratory conditions, with positive data emerging from trials targeting viral infection prevention and cystic fibrosis (CF)
You need to be a subscriber to read this article.
Click here to find out more.
Finance
Investing in the future of healthcare: from diagnostics innovation to scientific talent pipelines

Investing in the future of healthcare: from diagnostics innovation to scientific talent pipelines

Strategic UK investment in next-generation cancer diagnostics and cardiovascular research training is accelerating innovation, reducing barriers to adoption and building the multidisciplinary talent needed to deliver long-term improvements in patient outcomes and life sciences growth
You need to be a subscriber to read this article.
Click here to find out more.
Cell & Gene Therapy
Pairing up to advance CAR T cell therapies: a dual-targeting approach to solid tumours

Pairing up to advance CAR T cell therapies: a dual-targeting approach to solid tumours

A partnership between Link Cell Therapies and CTMC is advancing next-generation CAR T therapies for solid tumours by combining dual-targeting “logic-gated” engineering with integrated manufacturing and clinical development to improve precision, safety and speed to trials
You need to be a subscriber to read this article.
Click here to find out more.
Finance
Oncoinvent patent win and CellCarta deal highlight IP power in oncology innovation

Oncoinvent patent win and CellCarta deal highlight IP power in oncology innovation

New patent protection for Radspherin and a global exclusivity deal for Aspyre Lung underline how strong IP strategies are driving competitive advantage in cancer therapeutics and diagnostics
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery
From proof-of-concept to commercial reality: a turning point for microneedle drug delivery

From proof-of-concept to commercial reality: a turning point for microneedle drug delivery

A 50% reduction in microarray patch production costs demonstrates that scalable, automated MAP manufacturing is now commercially viable — clearing a critical barrier to mainstream pharmaceutical adoption
You need to be a subscriber to read this article.
Click here to find out more.
Finance
Industry partnerships strengthen biopharma innovation and manufacturing pathways

Industry partnerships strengthen biopharma innovation and manufacturing pathways

The life sciences sector continues to embrace strategic collaborations that bridge discovery and manufacturing gaps, with two major announcements highlighting industry momentum in early 2026